Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?

Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer? Andrew D. Seidman, Joyce O'Shaughnessy, Jean-Louis Misset Oncologist 2002; 7(Suppl 6): 20-28 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify evidence-based options for treatment of patients with taxane-refractory breast cancer. Explain reasons for and limitations of patient preference for oral chemotherapy. Manage treatment toxicities of capecitabine. Discuss the mechanism of action of capecitabine. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 27, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Nov. 27, 2002 Date Credit Expires: June 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Incorporating Oral Capecitabine into the Treatment of Breast Cancer.